Long-Term Debt
Pfizer Long-Term Debt decreased by 1.7% to $60.57B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.1%, from $57.64B to $60.57B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows an upward trend with a 10.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
High levels indicate significant financial leverage, which can increase interest expense and risk, while lower levels suggest a stronger balance sheet and greater financial flexibility.
Detailed definition
This represents the portion of debt obligations that are due beyond one year from the balance sheet date. For large phar...
Peer comparison
Commonly compared across the pharmaceutical sector to evaluate capital structure and debt-servicing capacity relative to EBITDA.
long_term_debtHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.35B | $36.25B | $36.2B | $35.66B | $34.29B | $32.63B | $32.88B | $31.7B | $61.36B | $61.05B | $61.54B | $61.31B | $57.51B | $58B | $57.41B | $57.64B | $57.5B | $57.41B | $61.64B | $60.57B |
| QoQ Change | — | +2.5% | -0.2% | -1.5% | -3.8% | -4.9% | +0.8% | -3.6% | +93.5% | -0.5% | +0.8% | -0.4% | -6.2% | +0.9% | -1.0% | +0.4% | -0.2% | -0.2% | +7.4% | -1.7% |
| YoY Change | — | — | — | — | -3.0% | -10.0% | -9.1% | -11.1% | +78.9% | +87.1% | +87.1% | +93.4% | -6.3% | -5.0% | -6.7% | -6.0% | -0.0% | -1.0% | +7.4% | +5.1% |
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Pfizer's long-term debt?
- Pfizer (PFE) reported long-term debt of $60.57B in Q1 2026.
- How has Pfizer's long-term debt changed year-over-year?
- Pfizer's long-term debt increased by 5.1% year-over-year, from $57.64B to $60.57B.
- What is the long-term trend for Pfizer's long-term debt?
- Over 5 years (2020 to 2025), Pfizer's long-term debt has grown at a 10.7% compound annual growth rate (CAGR), from $37.13B to $61.64B.
- What does long-term debt mean?
- Debt obligations that are not due for payment within the next twelve months.